Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Overview of attention for article published in Journal of Clinical Oncology, October 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 6 news outlets
twitter: 24 X users

guideline: 3 clinical guideline sources

Readers on

mendeley: 89 Mendeley

So far, Altmetric has seen 26 X posts from 24 X users, with an upper bound of 121,636 followers.

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study....LOLTA https://t.co/KQ4mN1MI9s

RT @Poudyalbishesh: Correct me if i am wrong ?? 1. Rituximab isn't standard of care 2. PFS in waldenstrom's as a primary end point .. not…

Correct me if i am wrong ?? 1. Rituximab isn't standard of care 2. PFS in waldenstrom's as a primary end point .. not easy to digest Ibrutinib Plus R Vs Placebo Plus Rituximab for Waldenström's Macroglobulinemia https://t.co/LtrbzJd4Fq @ManniMD1 @AaronG…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 22 additional X posts.